Overview

* Lifeloc Q3 2025 revenue increased 8% year-over-year to $2.257 mln

* Company reported a net loss of $263,000 for Q3 2025

* Gross margin decreased to 40.2% in Q3 due to cost inflation and tariffs

Outlook

* Lifeloc ( LCTC ) expects to launch SpinDetect™ in 2026

* Company sees rapid oral-fluid drug testing as key growth opportunity

* Lifeloc's ( LCTC ) acquisition of ELST aims to strengthen market reach

Result Drivers

* R&D COSTS - High research and development expenses for SpinDetect™ drug analyzer commercialization contributed to net loss

* COST INFLATION AND TARIFFS - Gross margin decline attributed to general cost inflation and tariffs, company plans pricing adjustments

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $2.26

Revenue mln

Q3 EPS -$0.10

Q3 Net -$263,00

Income 0

Q3 Gross 40.20%

Margin

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)